Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4431777?pdf=render |
| _version_ | 1819213259426758656 |
|---|---|
| author | Shuling Chen Lixia Huang Kaiyu Sun Dexi Wu Minrui Li Manying Li Bihui Zhong Minhu Chen Shenghong Zhang |
| author_facet | Shuling Chen Lixia Huang Kaiyu Sun Dexi Wu Minrui Li Manying Li Bihui Zhong Minhu Chen Shenghong Zhang |
| author_sort | Shuling Chen |
| collection | DOAJ |
| description | Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46-2.07), disease-free (HR 1.59, 95% CI: 1.27-1.99), metastasis-free (HR 2.19, 95% CI: 1.38-3.47), progression-free (HR 2.53, 95% CI: 1.52-4.21), cancer-specific (HR 3.13, 95% CI: 1.70-5.74), and disease-specific (HR 2.29, 95% CI: 1.56-3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93-2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07-9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37-6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49-4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33-6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11-0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23-0.39) in breast cancer.Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers. |
| first_indexed | 2024-12-23T06:56:01Z |
| format | Article |
| id | doaj.art-00c9233fe0dc43b786050606286b18ce |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T06:56:01Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-00c9233fe0dc43b786050606286b18ce2022-12-21T17:56:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012548010.1371/journal.pone.0125480Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.Shuling ChenLixia HuangKaiyu SunDexi WuMinrui LiManying LiBihui ZhongMinhu ChenShenghong ZhangNovel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46-2.07), disease-free (HR 1.59, 95% CI: 1.27-1.99), metastasis-free (HR 2.19, 95% CI: 1.38-3.47), progression-free (HR 2.53, 95% CI: 1.52-4.21), cancer-specific (HR 3.13, 95% CI: 1.70-5.74), and disease-specific (HR 2.29, 95% CI: 1.56-3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93-2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07-9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37-6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49-4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33-6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11-0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23-0.39) in breast cancer.Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.http://europepmc.org/articles/PMC4431777?pdf=render |
| spellingShingle | Shuling Chen Lixia Huang Kaiyu Sun Dexi Wu Minrui Li Manying Li Bihui Zhong Minhu Chen Shenghong Zhang Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. PLoS ONE |
| title | Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. |
| title_full | Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. |
| title_fullStr | Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. |
| title_full_unstemmed | Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. |
| title_short | Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis. |
| title_sort | enhancer of zeste homolog 2 as an independent prognostic marker for cancer a meta analysis |
| url | http://europepmc.org/articles/PMC4431777?pdf=render |
| work_keys_str_mv | AT shulingchen enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT lixiahuang enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT kaiyusun enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT dexiwu enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT minruili enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT manyingli enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT bihuizhong enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT minhuchen enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis AT shenghongzhang enhancerofzestehomolog2asanindependentprognosticmarkerforcancerametaanalysis |